Source: Annual Congress 2002 - Aspects of respiratory disease in primary care
Disease area: Airway diseases

Abstract

A 12-month, open label audit was conducted at 54 centres in The Netherlands. This study was designed to monitor safety of a new HFA-extrafine beclomethasone (3M Pharmaceuticals)(Qvar) and to evaluate patient[scquote]s well being. 316 patients with a range of asthma severity (84 patients with less than 80% predicted PEF) were switched from conventional inhaled steroids to extrafine beclomethasone at various dose-ratios according to patient need.
In this study most AEs were mild to moderate. The incidence of severe AEs after Qvar (5.1%) was comparable to the reviewed incidence of severe AEs after HFA-BDP (3.8%), CFC-BDP (6.8%) and HFA-placebo (8.7%) (1). Qvar administration provoked less cough (0.3%) than HFA-BDP (<1%), CFC-BDP (2%) or HFA-placebo (1%). Other inhalation-route AEs (dysphonia and taste perversion) were also less reported after Qvar (3.8%) in comparison with HFA-BDP (5%) and CFC-BDP (5%). The occurrence of respiratory system AEs (coughing) was similar (<1%) in Qvar, HFA-BDP, and HFA-placebo group.
The percentage of withdrawals due to AEs was lower after Qvar (3%) than after HFA-BDP (8%), CFC-BDP (10%) or HFA-placebo (21%). The safety results obtained in this study confirm tolerability to Qvar and safe switching from CFC-BDP. Qvar appears to represent an advance in the treatment of asthma.
1. Thompson P.J. et al. Respiratory Medicine 1998; 92: 33-39.

Rating:

Share or cite this content

Citations should be made in the following way:
C. P. van Schayck (). A pharmaco-epidemiological audit of beclomethasone dipropionate extrafine aerosol in patients with asthma. Eur Respir J 2002; 20: Suppl. 38, 2976

Member's Comments

No comment yet.

Related content which might interest you: HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005 Comparison of a new extrafine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006 Long-term benefits of switching to hydrofluoroalkane beclomethasone dipropionate extrafine aerosol Source: Eur Respir J 2001; 18: Suppl. 33, 331s Year: 2001 Salmeterol and beclomethasone dipropionate versus higher dose beclomethasone dipropionate in asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005 Clinical efficacy of seretide and beclomethasone dipropionate in patients with corticosteroid-dependent bronchial asthma and quality of life Source: Eur Respir J 2004; 24: Suppl. 48, 285s Year: 2004 Comparative clinical study of addition theophylline to low-dose inhaled beclomethasone dipropionate and medium-dose inhaled beclomethasone dipropionate in patients with mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 98s Year: 2001 HFA vs CFC beclomethasone dipropionate – comparative effectiveness in asthma management Source: Eur Respir J 2006; 28: Suppl. 50, 498s Year: 2006 The clinical effectiveness of HFA-beclomethasone dipropionate in children with moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 166s Year: 2004 QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009 Nebulized beclomethasone dipropionate is as effective and as well tolerated than nebulized budesonide to prevent asthma exacerbations in infants Source: Eur Respir J 2001; 18: Suppl. 33, 122s Year: 2001 Use of hydrofluoroalkane beclomethasone dipropionate (HFA-BDP) extrafine aerosol in optimising the management of allergic bronchopulmonary aspergillosis (ABPA) Source: Eur Respir J 2003; 22: Suppl. 45, 237s Year: 2003 Effects of the changing from chlorofluorocarbon (CFC)- beclomethasone dipropionate (BDP) to hydrofluoroalkane (HFA)-BDP on pulmonary function in asthmatic children Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma Year: 2007 Inhalation of beclomethason dipropionate spray compared with theophilline as primary treatment for chronic mild-to-moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002 Efficacy, safety and cost of using beclomethason dipropionate in patients with persistent moderate bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004 Real-life effectiveness of beclomethasone diproprionate/formoterol extra-fine combination in adult patients with persistent asthma Source: Annual Congress 2011 - Asthma management and response Year: 2011 Extrafine beclomethasone dipropionate aerosol therapy shows promising improved effect in treatment of children with stable asthma Source: Eur Respir J 2004; 24: Suppl. 48, 378s Year: 2004 Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006 Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Therapeutic equivalence of beclomethasone dipropionate/formoterol administered via NEXTTM DPI with beclomethasone dipropionate/formoterol administered via HFA pMDI in adult asthmatic patients Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010 QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009